Who Generates More Revenue? Amgen Inc. or Taro Pharmaceutical Industries Ltd.

Amgen's revenue dominance over Taro: A decade-long trend.

__timestampAmgen Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201420063000000759285000
Thursday, January 1, 201521662000000862944000
Friday, January 1, 201622991000000950751000
Sunday, January 1, 201722849000000879387000
Monday, January 1, 201823747000000661913000
Tuesday, January 1, 201923362000000669893000
Wednesday, January 1, 202025424000000644769000
Friday, January 1, 202125979000000548970000
Saturday, January 1, 202226323000000561347000
Sunday, January 1, 202328190000000572952000
Monday, January 1, 202433424000000629182000
Loading chart...

Infusing magic into the data realm

Revenue Showdown: Amgen Inc. vs. Taro Pharmaceutical Industries Ltd.

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market strength and innovation prowess. Over the past decade, Amgen Inc. has consistently outperformed Taro Pharmaceutical Industries Ltd. in terms of revenue. From 2014 to 2023, Amgen's revenue has grown by approximately 40%, peaking at $28.19 billion in 2023. In contrast, Taro's revenue has seen a decline, dropping to $572.95 million in 2023, a decrease of about 25% from its 2016 peak.

This stark contrast highlights Amgen's robust market strategies and product pipeline, which have enabled it to capture a larger market share. Meanwhile, Taro's revenue trajectory suggests challenges in maintaining its competitive edge. As we look to the future, the question remains: Can Taro revitalize its growth to challenge industry giants like Amgen?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025